Physician profile
Douglas Moore
NPI 1194729053
$7,033.49
in general payments reported to CMS, 2019-2025
21 companies · $2,362 in 2025
The $2,362 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $382 · 2021: $1,687 · 2022: $396 · 2023: $451 · 2024: $567 · 2025: $2,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754 · Travel and Lodging: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.99 |
| Travel and Lodging | $1,625.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,460.87 | 2019-2025 | Aveir |
| Medtronic, INC. | $1,987.89 | 2021-2025 | Micra, Selectsecure, Pulseselect |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $523.98 | 2020-2024 | Lifevest |
| Biosense Webster, INC. | $469.73 | 2019-2025 | Carto 3 |
| Medtronic Vascular, INC. | $259.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $193.34 | 2019-2024 | Camzyos |
| Stryker Corporation | $175.60 | 2022 | |
| Elutia, INC. | $173.17 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $143.76 | 2019 | |
| Altathera Pharmaceuticals LLC | $121.00 | 2025 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $109.50 | 2019 | |
| Boston Scientific Corporation | $90.56 | 2020-2024 | Mylux Patient Kit With Mobile Device, Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $74.59 | 2019-2022 | |
| Cardiva Medical, INC. | $74.13 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Esophageal Cooling Device |
| Sanofi-Aventis U.S. LLC | $50.84 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.47 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $27.25 | 2019 | |
| Daiichi Sankyo INC. | $25.08 | 2023 | Injectafer |
| Angiodynamics, INC. | $16.71 | 2020 | |
| Gilead Sciences, INC. | $11.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.